WO2017101210A1 - Gastritis treating traditional chinese medicine composition preparation method and preparation - Google Patents

Gastritis treating traditional chinese medicine composition preparation method and preparation Download PDF

Info

Publication number
WO2017101210A1
WO2017101210A1 PCT/CN2016/073419 CN2016073419W WO2017101210A1 WO 2017101210 A1 WO2017101210 A1 WO 2017101210A1 CN 2016073419 W CN2016073419 W CN 2016073419W WO 2017101210 A1 WO2017101210 A1 WO 2017101210A1
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
traditional chinese
chinese medicine
extract
powder
Prior art date
Application number
PCT/CN2016/073419
Other languages
French (fr)
Chinese (zh)
Inventor
陈致慜
马靖喧
李春雷
霍志金
Original Assignee
邯郸制药股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 邯郸制药股份有限公司 filed Critical 邯郸制药股份有限公司
Publication of WO2017101210A1 publication Critical patent/WO2017101210A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/896Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8967Lilium, e.g. tiger lily or Easter lily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/57Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • A61K36/07Basidiomycota, e.g. Cryptococcus
    • A61K36/076Poria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/23Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232Angelica
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/23Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/236Ligusticum (licorice-root)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/25Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258Panax (ginseng)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284Atractylodes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/54Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/65Paeoniaceae (Peony family), e.g. Chinese peony
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/66Papaveraceae (Poppy family), e.g. bloodroot
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/71Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/73Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/739Sanguisorba (burnet)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/80Scrophulariaceae (Figwort family)
    • A61K36/808Scrophularia (figwort)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/884Alismataceae (Water-plantain family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/896Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/896Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8968Ophiopogon (Lilyturf)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/898Orchidaceae (Orchid family)
    • A61K36/8984Dendrobium
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1664Compounds of unknown constitution, e.g. material from plants or animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2068Compounds of unknown constitution, e.g. material from plants or animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4875Compounds of unknown constitution, e.g. material from plants or animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/33Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50Methods involving additional extraction steps
    • A61K2236/53Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization

Definitions

  • the invention relates to a preparation method of a traditional Chinese medicine composition, in particular to a preparation method of a traditional Chinese medicine composition for treating gastritis and a pharmaceutical preparation prepared by the method.
  • Morodan is a drug that reduces the stomach, reduces spleen and swells, and relieves pain. For chronic atrophic gastritis and stomach pain, fullness, nausea, poor appetite, belching, heartburn and other symptoms. Dosage, oral, honey pill once 9 ⁇ 18g, 3 times a day, with rice soup or warm water before meals, or as directed.
  • Angelica has inhibitory effects on dysentery bacillus, Vibrio cholerae, Proteus and Escherichia coli.
  • Panax notoginseng saponins have strong inhibitory effects on certain fungi.
  • Atractylodes can effectively improve the humoral immune function in addition to the spleen.
  • the atractylodes are fried with bran, the eucalyptus is treated with vinegar, and the chicken is made of fried chicken.
  • Chinese patent 200710120838.4 discloses the following method for determining the content of Morodan.
  • the content is determined as follows:
  • Chromatographic conditions and system suitability test using octadecylsilane bonded silica as a filler; 15-60:40-85 acetonitrile-water as mobile phase; detection wavelength is 230nm, theoretical plate number calculated according to paeoniflorin peak Should not be less than 1000 ⁇ 5000;
  • Preparation of reference solution accurately weigh the appropriate amount of paeoniflorin reference substance, add methanol, ethanol, n-butanol, water, chloroform or ethyl acetate to make a solution containing 30-50 ⁇ g per 1ml, that is;
  • Preparation of the test solution Take the Morodan Xiaomi Pill or the big honey pill under the weight difference, and cut it. Weigh accurately 1 ⁇ 10g, add diatomaceous earth 1 ⁇ 10g, ground well, placed in a conical flask, precision added solvent methanol, ethanol, n-butanol, water, chloroform or ethyl acetate 15-25ml, Concealed, weighed, sonicated or hot reflux or cold soaked for 30 minutes, taken out and placed at room temperature, weighed, made up with solvent methanol, ethanol, n-butanol, water, chloroform or ethyl acetate to 15-25ml Shake well, filter, precision draw 4-6ml of the filtrate, put it in a 10ml volumetric flask, dilute to the mark with methanol, ethanol, n-butanol, water, chloroform or ethyl acetate, shake well, then get;
  • Determination method respectively, accurately draw the reference solution and the test solution 20 ⁇ l each, inject into the liquid chromatograph, determine, that is; Morotan per 1g containing white peony with paeoniflorin C 23 H 28 O 11 , not less than 0.8 Mg.
  • the present inventors have found in clinical and production practice that the prior art needs to be improved in terms of efficacy, stability, and raw material saving, in order to improve the action of the drug, prolong the storage period, reduce the amount of the drug, and improve the adaptability of the drug. To this end, the inventors have improved the prior art to complete the present invention.
  • the present invention provides a novel preparation method of Morodan, which is prepared as follows:
  • the preparation method is as follows:
  • Lily, Sanqi, Jiujinjin, Puhuang, Yanhusuo, Jiujiao Liupu six kinds of medicines are crushed into 80-200 mesh powder; the remaining medicine flavor is boiled 2-4 times with water, 0.5-3 hours each time, combined with liquid filtration and concentration
  • the extract to a relative density of 1.10 to 1.50; the powder is mixed with the extract to obtain a pharmaceutically active substance, and a pharmaceutical preparation composition is prepared by a formulation method.
  • the preparation method of the present invention is as follows:
  • a preferred preparation of the present invention is a concentrated pellet prepared by the following steps: taking a pharmaceutically active ingredient mixed with a powder and an extract, and adding 0.6-1.5 parts by weight of refined honey to 1 part by weight of the pulverized powder to prepare a concentrated honey pellet.
  • the method of the invention obviously increases the main active ingredient, the drug effect is obviously improved, and the stability of the preparation is obviously improved.
  • Animals were administered in groups. On the 7th day after administration, the animals in each group were fasted for 48 hours. Before the test, the animals in each group were re-administered (water) once. After 2 hours, each rat was given acid ethanol. 2ml (150mmol/L hydrochloric acid and 60% ethanol mixed in a ratio of 1:1). After 1h, the rats were anesthetized with an excess of ether, and the rats were sacrificed. The stomach was removed by abdomen. The cardia was clamped with a clip, and 5 ml of 1% formaldehyde solution was injected from the pylorus.
  • the length of gastric mucosal injury was calculated as the gastric mucosal injury index by the sum of the length of the injury (the doubling of the lesion width was greater than 1 mm), and the inhibition rate was calculated.
  • Control group 10 420 Model group 10 100 Group of the invention 10 345 Existing technology group 10 300
  • Animals were administered in groups of 10 rats. After the last administration, the animals in each group were fasted for 24 hours, anesthetized with ether, cut a small mouth along the midline of the abdomen, gently pulled out the stomach, ligated the pylorus, and then 12
  • the intestinal administration was performed once, and the abdominal wall incision was sutured. After 6 hours, the incision was opened and the cardia was ligated, the whole stomach was removed, the blood was removed by filter paper, the stomach wall was cut along the stomach, and the stomach contents were decanted and collected in a graduated centrifuge tube. Centrifuge at 1500r/min for 10min, accurately record the amount of gastric juice, determine the total acidity of gastric juice with phenol red as indicator, and measure the activity of pepsin by Mettle capillary method.
  • both the present invention group and the prior art group can reduce the total acidity of the gastric juice and the pepsin activity.
  • Both the present invention group and the prior art group can reduce the number of deaths of S. aureus infected mice and prolong the survival days of infected mice;
  • Both the present invention group and the prior art group can reduce the degree of swelling of the auricle caused by xylene in mice.
  • the dosage of the drug is lowered, the content of the active ingredient is increased, the stability of the preparation is improved, and the therapeutic effect of the drug is improved.
  • the preparation method is as follows:
  • the extract is mixed with the extract to obtain a pharmaceutically active substance, which is pelletized and dried to prepare a concentrated pellet; or the powder is mixed with the extract, granulated, and dried to form a capsule or tablet;
  • the preparation method is as follows:
  • Lily, Sanqi, Jiujinjin, Puhuang, Yanhusuo, Jiujie Zhangpu six-flavored medicine is pulverized into 80-200 mesh powder; the remaining medicinal taste is boiled twice with water for 0.5 hour, and the combined drug solution is filtered and concentrated to a relative density of 1.10. - 1.50 extract; the powder is mixed with the extract to obtain a pharmaceutically active substance, Pilling and drying to form a concentrated pill; or mixing the powder with the extract, granulating, and drying to form a capsule or tablet;
  • the preparation method is as follows:
  • the sample prepared by the method of the above examples was determined by a content measurement method: not less than 1.4 mg per 1 g of sputum containing paeoniflorin C 23 H 28 O 11 .

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Botany (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Provided are a method for preparing a traditional Chinese medicine composition for treating gastritis and a pharmaceutical preparation prepared by the same. The method comprises the following steps: grinding lily bulb, sanqi, inner membrane of chicken gizzard, cattail pollen, yanhusuo and rhizoma anemones altaicae into powder of 80-200 meshes; taking tuckahoe, figwort root, Sichuan lovage rhizome, lindera aggregata, oriental waterplantain rhizome, dwarf lilyturf tuber, largehead atractylodes rhizome, Chinese angelica, virgate wormwood herb, garden burnet root, ebark peony root and dendrobium for decocting in water, merging, filtering and concentrating the liquid medicine to get an extract with a relative density of 1.10-1.50; mixing the powder and the extract to get a drug active substance and to produce a pharmaceutical preparation composition. Products produced by this method have the characteristics of good stability and remarkable therapeutic effect etc.

Description

一种治疗胃炎的中药组合物制备方法及制剂Preparation method and preparation of traditional Chinese medicine composition for treating gastritis 发明领域Field of invention
本发明涉及一种中药组合物的制备方法,特别涉及用于治疗胃炎的中药组合物的制备方法以及用该方法制备的药物制剂。The invention relates to a preparation method of a traditional Chinese medicine composition, in particular to a preparation method of a traditional Chinese medicine composition for treating gastritis and a pharmaceutical preparation prepared by the method.
背景技术Background technique
摩罗丹是一种和胃降逆,健脾消胀,通络定痛的药物。用于慢性萎缩性胃炎及胃疼,胀满,痞闷,纳呆,嗳气,烧心等症。用法用量,口服,蜜丸一次9~18g,一日3次,饭前用米汤或温开水送下,或遵医嘱。其由百合、麦冬、石斛、茯苓、白术(麸炒)、乌药、白芍、三七、延胡索(醋炙)、鸡内金(炒香)、玄参、当归等18味中药制备而成,药理作用如下Morodan is a drug that reduces the stomach, reduces spleen and swells, and relieves pain. For chronic atrophic gastritis and stomach pain, fullness, nausea, poor appetite, belching, heartburn and other symptoms. Dosage, oral, honey pill once 9 ~ 18g, 3 times a day, with rice soup or warm water before meals, or as directed. It is prepared from 18 kinds of traditional Chinese medicines such as Lily, Ophiopogon japonicus, Dendrobium, Poria, Atractylodes Rhizome, Brassica oleracea L., Radix Paeoniae Alba, Radix Notoginseng, Yanhusuo (Vinegar), Chicken Inner Gold (Sautéed), Scrophulariaceae and Angelica. Cheng, pharmacological effects are as follows
1 作用:当归对痢疾杆菌、霍乱弧菌、变形杆菌、大肠杆菌均有抑制作用,三七总皂甙对某些真菌有较强抑制作用。1 Function: Angelica has inhibitory effects on dysentery bacillus, Vibrio cholerae, Proteus and Escherichia coli. Panax notoginseng saponins have strong inhibitory effects on certain fungi.
2 胃粘膜:本方对胃粘膜损伤有修复作用。2 gastric mucosa: This side has a repair effect on gastric mucosal damage.
3 药理研究乌药对胃肠道平滑肌有兴奋和抑制的双向调节作用,促进消化液分泌;鸡内金提高胃液分泌量,酸度和消化能力。3 Pharmacological studies Uygur medicine has two-way regulation of excitability and inhibition of gastrointestinal smooth muscle, promoting the secretion of digestive juice; chicken gold increases gastric secretion, acidity and digestion.
4 免疫功能:据药理性实验茯苓、白术除健脾外,还可有效提高体液免疫功能。4 Immune function: According to the pharmacological experiment, Atractylodes can effectively improve the humoral immune function in addition to the spleen.
5 药理发现本方中三七、当归、茯苓等皆有护肝、解除酒精肝中毒,促进肝中血清转化的功能。5 Pharmacology found that the party's Sanqi, Angelica, sputum, etc. have liver protection, relieve alcoholic liver poisoning, and promote the function of seroconversion in the liver.
中国专利公开了摩罗丹制剂的以下配方 The Chinese patent discloses the following formulation of the formulation of Morodan
Figure PCTCN2016073419-appb-000001
Figure PCTCN2016073419-appb-000001
所述白术用麸炒,延胡索用醋炙,鸡内金选用炒鸡内金。The atractylodes are fried with bran, the eucalyptus is treated with vinegar, and the chicken is made of fried chicken.
以及制备方法:And preparation method:
以上十八味,加水煎煮1-3次,每次1.5-3小时,合并煎液,滤过,滤液浓缩至适量,加入乙醇,使含醇量达60-80%,静置,滤过,回收乙醇,滤液浓缩,加水冷藏,滤过,最后经过常规工序直接或加入药学上可接受的赋型剂制成临床可接受的剂型。The above eighteen flavors, add water 1-3 times, each time 1.5-3 hours, combine the decoction, filter, the filtrate is concentrated to the appropriate amount, add ethanol, so that the alcohol content reaches 60-80%, let stand, filter The ethanol is recovered, the filtrate is concentrated, refrigerated with water, filtered, and finally a clinically acceptable dosage form is prepared by a conventional procedure directly or by adding a pharmaceutically acceptable excipient.
中国专利200710120838.4公开了摩罗丹以下含量测定方法,Chinese patent 200710120838.4 discloses the following method for determining the content of Morodan.
含量测定如下:The content is determined as follows:
照高效液相色谱法测定;Determined by high performance liquid chromatography;
色谱条件与系统适应性试验:用十八烷基硅烷键合硅胶为填充剂;以15-60:40-85的乙腈-水为流动相;检测波长为230nm,理论板数按芍药苷峰计算应不低于1000~5000;Chromatographic conditions and system suitability test: using octadecylsilane bonded silica as a filler; 15-60:40-85 acetonitrile-water as mobile phase; detection wavelength is 230nm, theoretical plate number calculated according to paeoniflorin peak Should not be less than 1000 ~ 5000;
对照品溶液的制备:精密称取芍药苷对照品适量,加溶剂甲醇、乙醇、正丁醇、水、三氯甲烷或乙酸乙酯制成每1ml含30-50μg的溶液,即得;Preparation of reference solution: accurately weigh the appropriate amount of paeoniflorin reference substance, add methanol, ethanol, n-butanol, water, chloroform or ethyl acetate to make a solution containing 30-50μg per 1ml, that is;
供试品溶液的制备:取摩罗丹小蜜丸或重量差异项下的大蜜丸,剪碎, 精密称取1~10g,加入硅藻土1~10g,研匀,置具塞锥形瓶中,精密加入溶剂甲醇、乙醇、正丁醇、水、三氯甲烷或乙酸乙酯15-25ml,密塞,称重,超声处理或热回流或冷浸提取30分钟,取出放至室温后称重,用溶剂甲醇、乙醇、正丁醇、水、三氯甲烷或乙酸乙酯补足至15-25ml摇匀,滤过,精密吸取续滤液4-6ml,置10ml量瓶中,加溶剂甲醇、乙醇、正丁醇、水、三氯甲烷或乙酸乙酯稀释至刻度,摇匀,即得;Preparation of the test solution: Take the Morodan Xiaomi Pill or the big honey pill under the weight difference, and cut it. Weigh accurately 1 ~ 10g, add diatomaceous earth 1 ~ 10g, ground well, placed in a conical flask, precision added solvent methanol, ethanol, n-butanol, water, chloroform or ethyl acetate 15-25ml, Concealed, weighed, sonicated or hot reflux or cold soaked for 30 minutes, taken out and placed at room temperature, weighed, made up with solvent methanol, ethanol, n-butanol, water, chloroform or ethyl acetate to 15-25ml Shake well, filter, precision draw 4-6ml of the filtrate, put it in a 10ml volumetric flask, dilute to the mark with methanol, ethanol, n-butanol, water, chloroform or ethyl acetate, shake well, then get;
测定法:分别精密吸取对照品溶液与供试品溶液各20μl,注入液相色谱仪,测定,即得;摩罗丹每1g含白芍以芍药苷C23H28O11计,不得少于0.8mg。Determination method: respectively, accurately draw the reference solution and the test solution 20μl each, inject into the liquid chromatograph, determine, that is; Morotan per 1g containing white peony with paeoniflorin C 23 H 28 O 11 , not less than 0.8 Mg.
本发明人在临床和生产实践中发现,现有技术在疗效,稳定性,原料的节约等方面需要改进,以提高药物的作用,延长储存期,减少药物的使用量,提高药物的适应性,为此本发明人对现有技术进行了改进,从而完成了本发明。The present inventors have found in clinical and production practice that the prior art needs to be improved in terms of efficacy, stability, and raw material saving, in order to improve the action of the drug, prolong the storage period, reduce the amount of the drug, and improve the adaptability of the drug. To this end, the inventors have improved the prior art to complete the present invention.
发明内容:Summary of the invention:
为改进现有技术的缺陷,本发明提供一种摩罗丹的新的制备方法,本发明所述方法,其配方如下:In order to improve the defects of the prior art, the present invention provides a novel preparation method of Morodan, which is prepared as follows:
Figure PCTCN2016073419-appb-000002
Figure PCTCN2016073419-appb-000002
Figure PCTCN2016073419-appb-000003
Figure PCTCN2016073419-appb-000003
其制备方法如下:The preparation method is as follows:
百合、三七、鸡内金、蒲黄、延胡索、九节菖蒲六味药粉碎成80-200目粉末;剩余药味加水煎煮2-4次,每次0.5-3小时,合并药液滤过浓缩至相对密度1.10-1.50的浸膏;粉末与浸膏混合得到药物活性物质,经过制剂方法,制备成药物制剂组合物。Lily, Sanqi, Jiujinjin, Puhuang, Yanhusuo, Jiujiao Liupu six kinds of medicines are crushed into 80-200 mesh powder; the remaining medicine flavor is boiled 2-4 times with water, 0.5-3 hours each time, combined with liquid filtration and concentration The extract to a relative density of 1.10 to 1.50; the powder is mixed with the extract to obtain a pharmaceutically active substance, and a pharmaceutical preparation composition is prepared by a formulation method.
优选的,本发明的制备方法如下:Preferably, the preparation method of the present invention is as follows:
百合、三七、鸡内金、蒲黄、延胡索、九节菖蒲六味药粉碎成100目粉末;剩余药味加水煎煮3次,每次2小时,合并药液滤过浓缩至相对密度1.10-1.50的浸膏;粉末与浸膏混合得到药物活性物质,经过制剂方法,制备成药物制剂组合物。Lily, Sanqi, Jiujinjin, Puhuang, Yanhusuo, Jiujiu Liupu six kinds of medicine pulverized into 100 mesh powder; the remaining medicinal taste and water decocted 3 times, each time for 2 hours, the combined drug solution was filtered and concentrated to a relative density of 1.10-1.50 The extract is mixed with the extract to obtain a pharmaceutically active substance, which is prepared into a pharmaceutical preparation composition by a formulation method.
本发明优选的制剂为浓缩丸,其制备方法如下,取粉末与浸膏混合的药物活性成分、粉碎后药粉每1重量份加0.6-1.5重量份炼蜜制成浓缩蜜丸。A preferred preparation of the present invention is a concentrated pellet prepared by the following steps: taking a pharmaceutically active ingredient mixed with a powder and an extract, and adding 0.6-1.5 parts by weight of refined honey to 1 part by weight of the pulverized powder to prepare a concentrated honey pellet.
本发明的方法和现有技术相比,主要活性成分明显增加,药效明显提高,制剂稳定性明显提高,Compared with the prior art, the method of the invention obviously increases the main active ingredient, the drug effect is obviously improved, and the stability of the preparation is obviously improved.
以下通过实验数据说明本发明的有益效果:The beneficial effects of the present invention are illustrated below by experimental data:
实验内容:Experimental content:
本发明和现有技术进行对比实验Comparative experiment between the present invention and prior art
实验1、对酸性乙醇致大鼠急性胃黏膜损伤的影响Experiment 1, the effect of acid ethanol on acute gastric mucosal injury in rats
动物分组给药,于给药第7天各组动物分别禁食不禁水48h,试验前各组动物再灌胃给药(水)1次,2h后每只大鼠灌胃酸性乙醇 2ml(150mmol/L盐酸与60%乙醇按1∶1比例混合),1h后分别用过量乙醚麻醉大鼠致死,开腹取胃,用夹子夹紧贲门,由幽门注入1%甲醛溶液5ml,夹紧幽门,将全胃置于1%甲醛溶液中固定10min,沿胃大弯剪开,将胃外翻,用清水轻轻洗去内容物,将胃平铺于玻璃板上,用精密卡尺测量胃黏膜损伤长度,以损伤长度(损伤宽度大于1mm者加倍计算)总和作为胃黏膜损伤指数,并计算抑制率。Animals were administered in groups. On the 7th day after administration, the animals in each group were fasted for 48 hours. Before the test, the animals in each group were re-administered (water) once. After 2 hours, each rat was given acid ethanol. 2ml (150mmol/L hydrochloric acid and 60% ethanol mixed in a ratio of 1:1). After 1h, the rats were anesthetized with an excess of ether, and the rats were sacrificed. The stomach was removed by abdomen. The cardia was clamped with a clip, and 5 ml of 1% formaldehyde solution was injected from the pylorus. Close the pylorus, put the whole stomach in 1% formaldehyde solution for 10min, cut it along the big curve of the stomach, turn the stomach out, gently wash the contents with water, spread the stomach on the glass plate, measure with precision caliper The length of gastric mucosal injury was calculated as the gastric mucosal injury index by the sum of the length of the injury (the doubling of the lesion width was greater than 1 mm), and the inhibition rate was calculated.
实验结果如下:The experimental results are as follows:
从结果可见,各组大鼠胃黏膜均有不同程度损伤,本发明组和现有技术组均较模型对照组轻,损伤指数明显降低(P<0.05)。It can be seen from the results that the gastric mucosa of each group had different degrees of damage. The present invention group and the prior art group were lighter than the model control group, and the injury index was significantly decreased (P<0.05).
大鼠再生粘膜厚度的比较Comparison of rat regenerative mucosal thickness
组别Group 动物数(只)Number of animals (only) 再生粘膜厚度(μm)Regenerated mucosal thickness (μm)
对照组Control group 1010 420420
模型组Model group 1010 100100
本发明组Group of the invention 1010 345345
现有技术组Existing technology group 1010 300300
溃疡灶肉芽瘢痕层厚度的比较Comparison of thickness of granulation scar layer in ulcerated stove
组别Group 动物数(只)Number of animals (only) 肉芽瘢痕层厚度(μm)Granulation scar thickness (μm)
对照组Control group 1010 00
模型组Model group 1010 0.60.6
本发明组Group of the invention 1010 0.160.16
现有技术组Existing technology group 1010 0.240.24
实验2、对大鼠胃液分泌的影响 Experiment 2, the effect on gastric juice secretion in rats
动物分组给药,每组10只大鼠,末次给药后各组动物分别禁食禁水24h,用乙醚麻醉,沿腹中线剪开小口,轻轻拉出胃,结扎幽门,再由十二指肠给药1次,缝合腹壁切口,6h后拆线开腹结扎贲门,摘除全胃,用滤纸擦净血迹,沿胃大弯剪开胃壁,倾出胃内容物,收集于刻度离心管中,以1500r/min速度离心10min,精确记录胃液量,以酚红为指示剂测定胃液总酸度,采用麦特毛细管法测定胃蛋白酶活性。Animals were administered in groups of 10 rats. After the last administration, the animals in each group were fasted for 24 hours, anesthetized with ether, cut a small mouth along the midline of the abdomen, gently pulled out the stomach, ligated the pylorus, and then 12 The intestinal administration was performed once, and the abdominal wall incision was sutured. After 6 hours, the incision was opened and the cardia was ligated, the whole stomach was removed, the blood was removed by filter paper, the stomach wall was cut along the stomach, and the stomach contents were decanted and collected in a graduated centrifuge tube. Centrifuge at 1500r/min for 10min, accurately record the amount of gastric juice, determine the total acidity of gastric juice with phenol red as indicator, and measure the activity of pepsin by Mettle capillary method.
实验结果如下:The experimental results are as follows:
从结果可见,本发明组和现有技术组均可降低胃液总酸度及胃蛋白酶活性。As can be seen from the results, both the present invention group and the prior art group can reduce the total acidity of the gastric juice and the pepsin activity.
Figure PCTCN2016073419-appb-000004
Figure PCTCN2016073419-appb-000004
实验3、体内抗菌试验:Experiment 3, in vivo antibacterial test:
本发明组和现有技术组均可以减少金黄色葡萄球菌感染小鼠死亡数,延长感染小鼠的存活天数;Both the present invention group and the prior art group can reduce the number of deaths of S. aureus infected mice and prolong the survival days of infected mice;
实验结果如下:The experimental results are as follows:
组别Group 动物数(只)Number of animals (only) 死亡数(只)Number of deaths (only) 存活率%Survival rate%
正常对照组Normal control group 2020 00 100100
模型组Model group 2020 1212 4040
本发明组Group of the invention 2020 66 7070
现有技术组Existing technology group 2020 99 5555
实验4.抗炎试验结果:Experiment 4. Anti-inflammatory test results:
本发明组和现有技术组均可降低二甲苯所致小鼠耳廓肿胀度。Both the present invention group and the prior art group can reduce the degree of swelling of the auricle caused by xylene in mice.
对小鼠迟发型变态反应(足跖增厚法)影响(足跖厚度差值mm)Effect on delayed type hypersensitivity in mice (ankle thickening method)
剂量组Dose group 动物数(只)Number of animals (only) 注射后24h足跖肿胀度(mm)Swelling degree of foot (24 mm) after injection
阴性对照组Negative control group 1010 0.2150.215
本发明组Group of the invention 1010 0.4650.465
现有技术组Existing technology group 1010 0.3460.346
实验5、加速稳定性实验Experiment 5, accelerated stability experiment
将样品放置在40℃±2℃、相对湿度75%±5%的条件下放置于恒温恒湿箱中,以设定时间取样,对有关成分进行含量测定,试验后的初步稳定性试验结果如下Place the sample in a constant temperature and humidity chamber under the condition of 40 °C ± 2 °C and relative humidity of 75% ± 5%. Sampling at the set time, the content of the relevant components is determined, and the preliminary stability test results after the test are as follows
本发明样品试验后的初步稳定性试验结果Preliminary stability test results after test of the sample of the present invention
Figure PCTCN2016073419-appb-000005
Figure PCTCN2016073419-appb-000005
Figure PCTCN2016073419-appb-000006
Figure PCTCN2016073419-appb-000006
现有技术样品试验后的初步稳定性试验结果Preliminary stability test results after testing of prior art samples
Figure PCTCN2016073419-appb-000007
Figure PCTCN2016073419-appb-000007
本发明的优点主要表现在:The advantages of the present invention are mainly manifested in:
通过改进制备方法,取得了以下技术效果:降低了药物的服用量,活性成分的含量有所提高,制剂稳定性有所提高,药物的疗效有所提高。By improving the preparation method, the following technical effects have been obtained: the dosage of the drug is lowered, the content of the active ingredient is increased, the stability of the preparation is improved, and the therapeutic effect of the drug is improved.
具体实施方式:detailed description:
以下通过实施例进一步说明本发明,但不作为对本发明的限制。The invention is further illustrated by the following examples without intending to limit the invention.
实施例1 Example 1
Figure PCTCN2016073419-appb-000008
Figure PCTCN2016073419-appb-000008
其制备方法如下:The preparation method is as follows:
百合、三七、鸡内金、蒲黄、延胡索、九节菖蒲六味药粉碎成100目粉末;剩余药味加水煎煮3次,每次2小时,合并药液滤过浓缩至相对密度1.10-1.50的浸膏;粉末与浸膏混合得到药物活性物质,制丸、干燥制成浓缩丸;或粉末与浸膏混合、制粒、干燥制成胶囊剂或片剂;Lily, Sanqi, Jiujinjin, Puhuang, Yanhusuo, Jiujiu Liupu six kinds of medicine pulverized into 100 mesh powder; the remaining medicinal taste and water decocted 3 times, each time for 2 hours, the combined drug solution was filtered and concentrated to a relative density of 1.10-1.50 The extract is mixed with the extract to obtain a pharmaceutically active substance, which is pelletized and dried to prepare a concentrated pellet; or the powder is mixed with the extract, granulated, and dried to form a capsule or tablet;
实施例2Example 2
Figure PCTCN2016073419-appb-000009
Figure PCTCN2016073419-appb-000009
其制备方法如下:The preparation method is as follows:
百合、三七、鸡内金、蒲黄、延胡索、九节菖蒲六味药粉碎成80-200目粉末;剩余药味加水煎煮2次,每次0.5小时,合并药液滤过浓缩至相对密度1.10-1.50的浸膏;粉末与浸膏混合得到药物活性物质, 制丸、干燥制成浓缩丸;或粉末与浸膏混合、制粒、干燥制成胶囊剂或片剂;Lily, Sanqi, Jiujinjin, Puhuang, Yanhusuo, Jiujie Zhangpu six-flavored medicine is pulverized into 80-200 mesh powder; the remaining medicinal taste is boiled twice with water for 0.5 hour, and the combined drug solution is filtered and concentrated to a relative density of 1.10. - 1.50 extract; the powder is mixed with the extract to obtain a pharmaceutically active substance, Pilling and drying to form a concentrated pill; or mixing the powder with the extract, granulating, and drying to form a capsule or tablet;
实施例3Example 3
Figure PCTCN2016073419-appb-000010
Figure PCTCN2016073419-appb-000010
其制备方法如下:The preparation method is as follows:
百合、三七、鸡内金、蒲黄、延胡索、九节菖蒲六味药粉碎成80-200目粉末;剩余药味加水煎煮4次,每次3小时,合并药液滤过浓缩至相对密度1.10-1.50的浸膏;粉末与浸膏混合、制丸、干燥制成浓缩丸;粉末与浸膏混合得到药物活性物质,制丸、干燥制成浓缩丸;或粉末与浸膏混合、制粒、干燥制成胶囊剂或片剂;Lily, notoginseng, chicken inner gold, puhuang, yanhusuo, nine-section calamus pulverized into 80-200 mesh powder; the remaining medicinal taste was boiled 4 times for 3 hours, and the combined drug solution was filtered and concentrated to a relative density of 1.10. - 1.50 of the extract; the powder is mixed with the extract, pelletized, and dried to prepare a concentrated pellet; the powder is mixed with the extract to obtain a pharmaceutically active substance, which is pelletized and dried to prepare a concentrated pellet; or the powder is mixed with the extract, granulated, Dry to make a capsule or tablet;
以上实施例方法制备的样品,经过含量测定法测定:每1g含白芍以芍药苷C23H28O11计,不少于1.4mg。 The sample prepared by the method of the above examples was determined by a content measurement method: not less than 1.4 mg per 1 g of sputum containing paeoniflorin C 23 H 28 O 11 .

Claims (7)

  1. 一种治疗胃炎的中药组合物的制备方法,所述中药组合物由以下重量配比的中药原料药制备而成,A preparation method of a traditional Chinese medicine composition for treating gastritis, wherein the traditional Chinese medicine composition is prepared from the following weight ratio traditional Chinese medicine raw material medicine,
    Figure PCTCN2016073419-appb-100001
    Figure PCTCN2016073419-appb-100001
    其特征在于,所述制备方法步骤如下:It is characterized in that the steps of the preparation method are as follows:
    百合、三七、鸡内金、蒲黄、延胡索、九节菖蒲六味药粉碎成80-200目粉末;剩余药味加水煎煮2-4次,每次0.5-3小时,合并药液滤过浓缩至相对密度1.10-1.50的浸膏;粉末与浸膏混合得到药物活性物质,经过制剂方法,制备成药物制剂组合物。Lily, Sanqi, Jiujinjin, Puhuang, Yanhusuo, Jiujiao Liupu six kinds of medicines are crushed into 80-200 mesh powder; the remaining medicine flavor is boiled 2-4 times with water, 0.5-3 hours each time, combined with liquid filtration and concentration The extract to a relative density of 1.10 to 1.50; the powder is mixed with the extract to obtain a pharmaceutically active substance, and a pharmaceutical preparation composition is prepared by a formulation method.
  2. 根据权利要求1所述的制备方法,其特征在于,所述中药组合物由以下重量配比的中药原料药制备而成,The preparation method according to claim 1, wherein the traditional Chinese medicine composition is prepared from the following weight ratio of traditional Chinese medicine raw materials.
    Figure PCTCN2016073419-appb-100002
    Figure PCTCN2016073419-appb-100002
    Figure PCTCN2016073419-appb-100003
    Figure PCTCN2016073419-appb-100003
    其特征在于,所述制备方法步骤如下:It is characterized in that the steps of the preparation method are as follows:
    百合、三七、鸡内金、蒲黄、延胡索、九节菖蒲六味药粉碎成80-200目粉末;剩余药味加水煎煮2-4次,每次0.5-3小时,合并药液滤过浓缩至相对密度1.10-1.50的浸膏;粉末与浸膏混合得到药物活性物质,经过制剂方法,制备成药物制剂组合物。Lily, Sanqi, Jiujinjin, Puhuang, Yanhusuo, Jiujiao Liupu six kinds of medicines are crushed into 80-200 mesh powder; the remaining medicine flavor is boiled 2-4 times with water, 0.5-3 hours each time, combined with liquid filtration and concentration The extract to a relative density of 1.10 to 1.50; the powder is mixed with the extract to obtain a pharmaceutically active substance, and a pharmaceutical preparation composition is prepared by a formulation method.
  3. 根据权利要求1所述的制备方法,其特征在于,所述中药组合物由以下重量配比的中药原料药制备而成,The preparation method according to claim 1, wherein the traditional Chinese medicine composition is prepared from the following weight ratio of traditional Chinese medicine raw materials.
    Figure PCTCN2016073419-appb-100004
    Figure PCTCN2016073419-appb-100004
    其特征在于,所述制备方法步骤如下:It is characterized in that the steps of the preparation method are as follows:
    百合、三七、鸡内金、蒲黄、延胡索、九节菖蒲六味药粉碎成100目粉末;剩余药味加水煎煮3次,每次2小时,合并药液滤过浓缩至相对密度1.10-1.50的浸膏;粉末与浸膏混合得到药物活性物质,经过制剂方法,制备成药物制剂组合物。Lily, Sanqi, Jiujinjin, Puhuang, Yanhusuo, Jiujiu Liupu six kinds of medicine pulverized into 100 mesh powder; the remaining medicinal taste and water decocted 3 times, each time for 2 hours, the combined drug solution was filtered and concentrated to a relative density of 1.10-1.50 The extract is mixed with the extract to obtain a pharmaceutically active substance, which is prepared into a pharmaceutical preparation composition by a formulation method.
  4. 根据权利要求1所述的制备方法,其特征在于,所述中药组合物由以下重量配比的中药原料药制备而成,The preparation method according to claim 1, wherein the traditional Chinese medicine composition is prepared from the following weight ratio of traditional Chinese medicine raw materials.
    Figure PCTCN2016073419-appb-100005
    Figure PCTCN2016073419-appb-100005
    Figure PCTCN2016073419-appb-100006
    Figure PCTCN2016073419-appb-100006
    其特征在于,所述制备方法步骤如下:It is characterized in that the steps of the preparation method are as follows:
    百合、三七、鸡内金、蒲黄、延胡索、九节菖蒲六味药粉碎成100目粉末;剩余药味加水煎煮3次,每次2小时,合并药液滤过浓缩至相对密度1.10-1.50的浸膏;粉末与浸膏混合得到药物活性物质,制丸、干燥制成浓缩丸;或粉末与浸膏混合、制粒、干燥制成胶囊剂或片剂。Lily, Sanqi, Jiujinjin, Puhuang, Yanhusuo, Jiujiu Liupu six kinds of medicine pulverized into 100 mesh powder; the remaining medicinal taste and water decocted 3 times, each time for 2 hours, the combined drug solution was filtered and concentrated to a relative density of 1.10-1.50 The extract is mixed with the extract to obtain a pharmaceutically active substance, which is pelletized and dried to prepare a concentrated pellet; or the powder is mixed with the extract, granulated, and dried to form a capsule or tablet.
  5. 根据权利要求1所述的制备方法,其特征在于,所述中药组合物为浓缩丸,含浓缩水丸、浓缩蜜丸、浓缩水蜜丸。The preparation method according to claim 1, wherein the traditional Chinese medicine composition is a concentrated pill comprising concentrated water pill, concentrated pill, and concentrated water pill.
  6. 根据权利要求1所述的制备方法,其特征在于,所述中药组合物为胶囊剂。The preparation method according to claim 1, wherein the traditional Chinese medicine composition is a capsule.
  7. 根据权利要求1所述的制备方法,其特征在于,所述中药组合物为片剂。 The preparation method according to claim 1, wherein the traditional Chinese medicine composition is a tablet.
PCT/CN2016/073419 2015-12-16 2016-02-04 Gastritis treating traditional chinese medicine composition preparation method and preparation WO2017101210A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510939828.8 2015-12-16
CN201510939828.8A CN105477361B (en) 2015-12-16 2015-12-16 A kind of Chinese medicine composition preparation method that treating gastritis and preparation

Publications (1)

Publication Number Publication Date
WO2017101210A1 true WO2017101210A1 (en) 2017-06-22

Family

ID=55664872

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2016/073419 WO2017101210A1 (en) 2015-12-16 2016-02-04 Gastritis treating traditional chinese medicine composition preparation method and preparation

Country Status (2)

Country Link
CN (1) CN105477361B (en)
WO (1) WO2017101210A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115990203A (en) * 2021-10-18 2023-04-21 林玉枝 A preparation containing folium Malloti Apeltae component for preventing and treating chronic atrophic gastritis and its application

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113262217A (en) * 2021-02-24 2021-08-17 邯郸制药股份有限公司 Substance for protecting gastric mucosa and preparation and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1286101A (en) * 2000-09-11 2001-03-07 李恩复 Medicine for treating atrophic gastritis and its preparing process
CN1457829A (en) * 2003-04-17 2003-11-26 邯郸制药有限公司 Chinese medicine composition for curing chronic atrophic sastritis and its preparing method and quality control method

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1840091A (en) * 2005-04-02 2006-10-04 周宇 Novel medicine for treating atrophic gastritis and preparation method thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1286101A (en) * 2000-09-11 2001-03-07 李恩复 Medicine for treating atrophic gastritis and its preparing process
CN1457829A (en) * 2003-04-17 2003-11-26 邯郸制药有限公司 Chinese medicine composition for curing chronic atrophic sastritis and its preparing method and quality control method

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YU , ZHEN ET AL.: "Muo-luo-dan Concentrated Pill in Treatment of Chronic Atrophic Gastritis (the Stomach-yin of Deficiency and Stagnated Blood of Stomach Meridian): A Prospective, Randomized, Controlled Trial", WEST CHINA MEDICAL JOURNAL, vol. 22, no. 2, 25 April 2007 (2007-04-25), pages 287 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115990203A (en) * 2021-10-18 2023-04-21 林玉枝 A preparation containing folium Malloti Apeltae component for preventing and treating chronic atrophic gastritis and its application
CN115990203B (en) * 2021-10-18 2023-12-26 林玉枝 A preparation containing folium Malloti Apeltae component for preventing and treating chronic atrophic gastritis and its application

Also Published As

Publication number Publication date
CN105477361A (en) 2016-04-13
CN105477361B (en) 2019-06-28

Similar Documents

Publication Publication Date Title
KR102123972B1 (en) Pharmaceutical composition for treating headache, and preparation method thereof
KR101088539B1 (en) Chinese medicinal compositions for treating headache, formulations and processes for preparation therof
WO2017113476A1 (en) Traditional chinese medicine composition for treating gastritis
WO2017101210A1 (en) Gastritis treating traditional chinese medicine composition preparation method and preparation
CN105477359B (en) A kind of Chinese medicine composition preparation method that treating gastritis and preparation
WO2017113475A1 (en) Traditional chinese medicine composition for treating gastritis
CN105477360B (en) A kind of Chinese medicine composition preparation method that treating gastritis and preparation
CN105456738A (en) Preparation method and preparation of traditional Chinese medicinal composition for treating gastritis
WO2014090122A1 (en) Pharmaceutical compositions for reducing sugar level, preparation methods and applications thereof
CN101502536B (en) Cedar total flavone as well as preparation method and medical use
CN105477362A (en) Preparation method of traditional Chinese medicinal composition for treating gastritis and preparation prepared by adopting preparation method
CN105497557A (en) Preparation method for traditional Chinese medicine composition for treating gastritis and preparation
CN105327149B (en) A kind of Chinese medicine composition preparation method that treating gastritis and preparation
CN105477364B (en) A kind of Chinese medicine composition preparation method that treating gastritis and preparation
CN105395889B (en) A kind of Chinese medicine composition preparation method that treating gastritis and preparation
CN105477358A (en) Preparation method and preparation of traditional Chinese medicinal composition for treating gastritis
CN105381259B (en) A kind of Chinese medicine composition preparation method that treating gastritis and preparation
CN109432193B (en) Pharmaceutical composition for treating cough and preparation method thereof
CN106620440B (en) Prescription for cough
CN105456737A (en) Preparation method and preparation of traditional Chinese medicinal composition for treating gastritis
CN105477363A (en) Preparation method of traditional Chinese medicinal composition for treating gastritis and preparation prepared by adopting preparation method
CN104491192B (en) A kind of pharmaceutical preparation of anticancer pill and preparation method thereof
CN105381257A (en) Traditional Chinese medicine composition for treating gastritis and preparation thereof
CN117919346A (en) Medicinal and edible traditional Chinese medicine compound for treating hyperuricemia and gouty arthritis and application thereof
CN117771289A (en) Traditional Chinese medicine composition for treating viral upper respiratory tract infection as well as preparation method and application thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16874276

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16874276

Country of ref document: EP

Kind code of ref document: A1